BioLineRx Future Growth
Future criteria checks 2/6
BioLineRx is forecast to grow earnings and revenue by 34.4% and 27.8% per annum respectively while EPS is expected to decline by 11.2% per annum.
Key information
34.4%
Earnings growth rate
-11.2%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 27.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 25 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 35 | -28 | -19 | -19 | 2 |
| 12/31/2025 | 21 | -40 | -34 | -34 | 2 |
| 12/31/2024 | 22 | -11 | -59 | -44 | 3 |
| 6/30/2024 | 17 | -30 | -30 | -30 | N/A |
| 3/31/2024 | 12 | -49 | -29 | -29 | N/A |
| 12/31/2023 | 5 | -61 | -23 | -23 | N/A |
| 9/30/2023 | N/A | -52 | -34 | -33 | N/A |
| 6/30/2023 | N/A | -43 | -33 | -32 | N/A |
| 3/31/2023 | N/A | -32 | -29 | -29 | N/A |
| 12/31/2022 | N/A | -25 | -27 | -26 | N/A |
| 9/30/2022 | N/A | -24 | -26 | -26 | N/A |
| 6/30/2022 | N/A | -22 | -23 | -22 | N/A |
| 3/31/2022 | N/A | -22 | -23 | -23 | N/A |
| 12/31/2021 | N/A | -27 | -24 | -24 | N/A |
| 9/30/2021 | N/A | -35 | -24 | -24 | N/A |
| 6/30/2021 | N/A | -34 | -24 | -24 | N/A |
| 3/31/2021 | N/A | -34 | -23 | -23 | N/A |
| 12/31/2020 | N/A | -30 | -23 | -23 | N/A |
| 9/30/2020 | N/A | -28 | -23 | -23 | N/A |
| 6/30/2020 | N/A | -27 | -24 | -24 | N/A |
| 3/31/2020 | N/A | -26 | -25 | -25 | N/A |
| 12/31/2019 | N/A | -25 | -23 | -23 | N/A |
| 9/30/2019 | N/A | -21 | -33 | -22 | N/A |
| 6/30/2019 | N/A | -24 | -32 | -22 | N/A |
| 3/31/2019 | N/A | -23 | -32 | -22 | N/A |
| 12/31/2018 | N/A | -23 | -34 | -24 | N/A |
| 9/30/2018 | N/A | -25 | -26 | -25 | N/A |
| 6/30/2018 | N/A | -26 | -26 | -26 | N/A |
| 3/31/2018 | N/A | -26 | N/A | -24 | N/A |
| 12/31/2017 | N/A | -24 | N/A | -21 | N/A |
| 9/30/2017 | N/A | -21 | N/A | -18 | N/A |
| 6/30/2017 | N/A | -18 | N/A | -15 | N/A |
| 3/31/2017 | N/A | -17 | N/A | -14 | N/A |
| 12/31/2016 | N/A | -16 | N/A | -15 | N/A |
| 9/30/2016 | N/A | -15 | N/A | -14 | N/A |
| 6/30/2016 | N/A | -13 | N/A | -14 | N/A |
| 3/31/2016 | N/A | -14 | N/A | -15 | N/A |
| 12/31/2015 | N/A | -14 | N/A | -14 | N/A |
| 9/30/2015 | N/A | -15 | N/A | -16 | N/A |
| 6/30/2015 | N/A | -14 | N/A | -15 | N/A |
| 3/31/2015 | N/A | -13 | N/A | -16 | N/A |
| 12/31/2014 | N/A | -11 | N/A | -16 | N/A |
| 9/30/2014 | N/A | -11 | N/A | -15 | N/A |
| 6/30/2014 | N/A | -16 | N/A | -16 | N/A |
| 3/31/2014 | N/A | -16 | N/A | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YP2A is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: YP2A is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: YP2A is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: YP2A's revenue (27.8% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: YP2A's revenue (27.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if YP2A's Return on Equity is forecast to be high in 3 years time